Linda Cook
Concepts (214)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endometrial Neoplasms | 16 | 2025 | 205 | 2.750 |
Why?
| | Ovarian Neoplasms | 14 | 2024 | 604 | 2.130 |
Why?
| | Neoplasms, Glandular and Epithelial | 4 | 2016 | 52 | 1.160 |
Why?
| | Biomarkers, Tumor | 9 | 2024 | 1339 | 1.010 |
Why?
| | Contraceptives, Oral, Combined | 2 | 2016 | 18 | 0.890 |
Why?
| | Triple Negative Breast Neoplasms | 5 | 2026 | 220 | 0.880 |
Why?
| | Breast Neoplasms | 10 | 2025 | 2418 | 0.880 |
Why?
| | Sex Hormone-Binding Globulin | 1 | 2019 | 51 | 0.600 |
Why?
| | Birth Order | 2 | 2016 | 15 | 0.590 |
Why?
| | Alberta | 9 | 2025 | 25 | 0.590 |
Why?
| | Gonadal Steroid Hormones | 1 | 2019 | 143 | 0.550 |
Why?
| | Carcinoma, Endometrioid | 4 | 2024 | 49 | 0.520 |
Why?
| | Immunohistochemistry | 8 | 2024 | 1712 | 0.510 |
Why?
| | Case-Control Studies | 13 | 2025 | 3647 | 0.490 |
Why?
| | Bone Neoplasms | 3 | 2026 | 272 | 0.470 |
Why?
| | Alcohol Drinking | 3 | 2024 | 850 | 0.430 |
Why?
| | Colorectal Neoplasms | 2 | 2022 | 874 | 0.410 |
Why?
| | Risk Factors | 21 | 2025 | 10921 | 0.390 |
Why?
| | Female | 48 | 2026 | 79499 | 0.360 |
Why?
| | Canada | 4 | 2019 | 432 | 0.360 |
Why?
| | Aged | 25 | 2026 | 26432 | 0.340 |
Why?
| | Contraception | 1 | 2013 | 170 | 0.340 |
Why?
| | Parity | 4 | 2025 | 113 | 0.340 |
Why?
| | Receptors, Progesterone | 5 | 2026 | 242 | 0.330 |
Why?
| | Cancer Survivors | 4 | 2024 | 348 | 0.320 |
Why?
| | Middle Aged | 27 | 2026 | 36619 | 0.320 |
Why?
| | Neoplasms, Cystic, Mucinous, and Serous | 2 | 2020 | 27 | 0.310 |
Why?
| | Humans | 51 | 2026 | 146342 | 0.280 |
Why?
| | SEER Program | 2 | 2022 | 233 | 0.270 |
Why?
| | Receptors, Estrogen | 4 | 2026 | 406 | 0.270 |
Why?
| | Social Support | 2 | 2023 | 646 | 0.260 |
Why?
| | Adult | 20 | 2026 | 41087 | 0.250 |
Why?
| | Contraceptives, Oral | 3 | 2025 | 37 | 0.250 |
Why?
| | Adenocarcinoma, Mucinous | 2 | 2019 | 76 | 0.240 |
Why?
| | Menopause, Premature | 2 | 2024 | 12 | 0.230 |
Why?
| | Diphosphonates | 1 | 2026 | 68 | 0.230 |
Why?
| | Bone Density Conservation Agents | 1 | 2026 | 83 | 0.230 |
Why?
| | Miners | 1 | 2025 | 3 | 0.220 |
Why?
| | Mosaicism | 2 | 2016 | 67 | 0.220 |
Why?
| | Body Mass Index | 4 | 2025 | 2458 | 0.220 |
Why?
| | British Columbia | 4 | 2020 | 27 | 0.220 |
Why?
| | Prospective Studies | 9 | 2024 | 8123 | 0.210 |
Why?
| | PAX2 Transcription Factor | 1 | 2024 | 8 | 0.210 |
Why?
| | Cohort Studies | 7 | 2026 | 6077 | 0.200 |
Why?
| | Neoplasms, Second Primary | 1 | 2024 | 103 | 0.200 |
Why?
| | Tissue Array Analysis | 2 | 2020 | 49 | 0.190 |
Why?
| | Point-of-Care Systems | 1 | 2025 | 185 | 0.180 |
Why?
| | Workplace | 1 | 2025 | 268 | 0.180 |
Why?
| | Cystadenocarcinoma, Serous | 1 | 2023 | 90 | 0.180 |
Why?
| | Genital Neoplasms, Female | 1 | 2024 | 100 | 0.180 |
Why?
| | Young Adult | 9 | 2025 | 14330 | 0.180 |
Why?
| | Bronchitis, Chronic | 1 | 2022 | 16 | 0.180 |
Why?
| | Sterilization, Tubal | 2 | 2024 | 17 | 0.180 |
Why?
| | Dogs | 1 | 2023 | 517 | 0.180 |
Why?
| | Genetic Predisposition to Disease | 5 | 2021 | 2488 | 0.170 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2026 | 1160 | 0.170 |
Why?
| | Cigarette Smoking | 1 | 2023 | 103 | 0.170 |
Why?
| | Proportional Hazards Models | 5 | 2026 | 1331 | 0.170 |
Why?
| | Horticultural Therapy | 1 | 2021 | 1 | 0.170 |
Why?
| | Neoplasm Grading | 2 | 2020 | 313 | 0.170 |
Why?
| | DNA Mutational Analysis | 2 | 2020 | 410 | 0.170 |
Why?
| | Menopause | 3 | 2024 | 328 | 0.170 |
Why?
| | DNA Mismatch Repair | 1 | 2021 | 54 | 0.170 |
Why?
| | Gardening | 1 | 2021 | 13 | 0.170 |
Why?
| | Risk | 3 | 2019 | 920 | 0.170 |
Why?
| | Logistic Models | 3 | 2024 | 2126 | 0.170 |
Why?
| | Odds Ratio | 5 | 2025 | 1077 | 0.170 |
Why?
| | Genome-Wide Association Study | 4 | 2016 | 1537 | 0.170 |
Why?
| | Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2021 | 42 | 0.170 |
Why?
| | Early Detection of Cancer | 1 | 2026 | 506 | 0.160 |
Why?
| | New Mexico | 2 | 2021 | 106 | 0.160 |
Why?
| | Cyclin E | 1 | 2020 | 23 | 0.160 |
Why?
| | Vegetables | 1 | 2021 | 159 | 0.160 |
Why?
| | Socioeconomic Factors | 2 | 2022 | 1327 | 0.150 |
Why?
| | Washington | 2 | 2020 | 157 | 0.150 |
Why?
| | Oncogene Proteins | 1 | 2020 | 61 | 0.150 |
Why?
| | Pregnancy | 4 | 2020 | 7230 | 0.150 |
Why?
| | Gene Amplification | 1 | 2020 | 116 | 0.150 |
Why?
| | Social Class | 1 | 2022 | 260 | 0.150 |
Why?
| | Rural Population | 1 | 2025 | 677 | 0.150 |
Why?
| | Keratin-7 | 1 | 2019 | 3 | 0.150 |
Why?
| | Matrix Attachment Region Binding Proteins | 1 | 2019 | 6 | 0.150 |
Why?
| | Mentors | 1 | 2021 | 217 | 0.140 |
Why?
| | Gene Expression Regulation, Neoplastic | 3 | 2020 | 1432 | 0.140 |
Why?
| | Carcinoma | 1 | 2020 | 225 | 0.140 |
Why?
| | Emotions | 1 | 2023 | 559 | 0.140 |
Why?
| | Age Factors | 3 | 2025 | 3347 | 0.130 |
Why?
| | Lung Diseases | 1 | 2024 | 787 | 0.130 |
Why?
| | Obesity | 3 | 2023 | 3131 | 0.130 |
Why?
| | Ovary | 1 | 2019 | 236 | 0.130 |
Why?
| | Surveys and Questionnaires | 4 | 2023 | 6073 | 0.130 |
Why?
| | Observer Variation | 3 | 2024 | 356 | 0.130 |
Why?
| | Coffee | 1 | 2016 | 16 | 0.120 |
Why?
| | Tea | 1 | 2016 | 17 | 0.120 |
Why?
| | X Chromosome Inactivation | 1 | 2016 | 25 | 0.120 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2020 | 530 | 0.120 |
Why?
| | Beverages | 1 | 2016 | 67 | 0.120 |
Why?
| | Algorithms | 2 | 2026 | 1849 | 0.120 |
Why?
| | Caffeine | 1 | 2016 | 77 | 0.120 |
Why?
| | Chromosomes, Human, X | 1 | 2016 | 76 | 0.120 |
Why?
| | Guideline Adherence | 1 | 2020 | 594 | 0.120 |
Why?
| | Neoplasms, Complex and Mixed | 1 | 2015 | 7 | 0.120 |
Why?
| | Reproducibility of Results | 5 | 2024 | 3416 | 0.110 |
Why?
| | United States | 5 | 2026 | 16136 | 0.110 |
Why?
| | Glycemic Load | 1 | 2015 | 2 | 0.110 |
Why?
| | Diet | 1 | 2023 | 1273 | 0.110 |
Why?
| | Chromosome Aberrations | 1 | 2015 | 167 | 0.100 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2022 | 928 | 0.100 |
Why?
| | Incidence | 2 | 2023 | 2936 | 0.100 |
Why?
| | Predictive Value of Tests | 4 | 2021 | 2113 | 0.100 |
Why?
| | Quality of Life | 2 | 2023 | 3200 | 0.100 |
Why?
| | Registries | 2 | 2020 | 2400 | 0.100 |
Why?
| | Insulin-Like Growth Factor Binding Protein 3 | 1 | 2013 | 32 | 0.100 |
Why?
| | TNF-Related Apoptosis-Inducing Ligand | 1 | 2013 | 54 | 0.100 |
Why?
| | Interleukin-1alpha | 1 | 2013 | 55 | 0.100 |
Why?
| | Membrane Glycoproteins | 1 | 2016 | 495 | 0.100 |
Why?
| | Diagnosis, Differential | 3 | 2024 | 1503 | 0.100 |
Why?
| | Insulin Resistance | 1 | 2022 | 1247 | 0.100 |
Why?
| | Breast Feeding | 1 | 2017 | 447 | 0.100 |
Why?
| | Smoking | 3 | 2025 | 1486 | 0.100 |
Why?
| | Exome | 1 | 2014 | 233 | 0.090 |
Why?
| | Population Surveillance | 1 | 2016 | 481 | 0.090 |
Why?
| | Breast | 1 | 2013 | 155 | 0.090 |
Why?
| | Hypertension | 1 | 2021 | 1272 | 0.090 |
Why?
| | Genome, Human | 1 | 2015 | 431 | 0.090 |
Why?
| | Neoplasms | 2 | 2026 | 2954 | 0.090 |
Why?
| | Health Services Accessibility | 1 | 2020 | 1107 | 0.090 |
Why?
| | BRCA2 Protein | 2 | 2023 | 69 | 0.090 |
Why?
| | BRCA1 Protein | 2 | 2023 | 84 | 0.090 |
Why?
| | Postmenopause | 1 | 2013 | 394 | 0.080 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2013 | 320 | 0.080 |
Why?
| | Practice Guidelines as Topic | 1 | 2019 | 1591 | 0.080 |
Why?
| | Overweight | 1 | 2016 | 614 | 0.080 |
Why?
| | Transcription Factors | 1 | 2019 | 1730 | 0.080 |
Why?
| | Comorbidity | 1 | 2016 | 1665 | 0.080 |
Why?
| | Aged, 80 and over | 3 | 2024 | 8391 | 0.080 |
Why?
| | NF-kappa B | 1 | 2013 | 674 | 0.080 |
Why?
| | Prevalence | 3 | 2024 | 2861 | 0.080 |
Why?
| | Hypoglycemic Agents | 1 | 2019 | 1412 | 0.070 |
Why?
| | Mutation | 1 | 2020 | 4093 | 0.070 |
Why?
| | Lung Neoplasms | 1 | 2022 | 2675 | 0.070 |
Why?
| | Vitamin D | 2 | 2025 | 402 | 0.060 |
Why?
| | Premenopause | 2 | 2019 | 130 | 0.060 |
Why?
| | National Cancer Institute (U.S.) | 1 | 2026 | 56 | 0.060 |
Why?
| | Signal Transduction | 2 | 2024 | 5246 | 0.060 |
Why?
| | Aging | 1 | 2016 | 1996 | 0.050 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2019 | 2623 | 0.050 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2026 | 1763 | 0.050 |
Why?
| | Menarche | 1 | 2025 | 53 | 0.050 |
Why?
| | Carbonyl Reductase (NADPH) | 1 | 2024 | 5 | 0.050 |
Why?
| | Wnt4 Protein | 1 | 2024 | 19 | 0.050 |
Why?
| | Neurofibromin 1 | 1 | 2023 | 26 | 0.050 |
Why?
| | Animals | 2 | 2023 | 38106 | 0.050 |
Why?
| | Estrogen Replacement Therapy | 1 | 2024 | 144 | 0.050 |
Why?
| | Hormone Replacement Therapy | 1 | 2024 | 107 | 0.050 |
Why?
| | Polymorphism, Single Nucleotide | 3 | 2016 | 2240 | 0.050 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2024 | 193 | 0.050 |
Why?
| | Survival Analysis | 2 | 2016 | 1378 | 0.040 |
Why?
| | Waist-Hip Ratio | 1 | 2022 | 37 | 0.040 |
Why?
| | Feasibility Studies | 1 | 2026 | 1135 | 0.040 |
Why?
| | Ligands | 1 | 2024 | 678 | 0.040 |
Why?
| | Waist Circumference | 1 | 2022 | 142 | 0.040 |
Why?
| | Smokers | 1 | 2022 | 139 | 0.040 |
Why?
| | Healthy Lifestyle | 1 | 2021 | 38 | 0.040 |
Why?
| | Forced Expiratory Volume | 1 | 2022 | 451 | 0.040 |
Why?
| | ROC Curve | 1 | 2023 | 617 | 0.040 |
Why?
| | Risk Assessment | 2 | 2020 | 3712 | 0.040 |
Why?
| | Phenotype | 2 | 2021 | 3206 | 0.040 |
Why?
| | Genotype | 2 | 2016 | 1879 | 0.040 |
Why?
| | Adiponectin | 1 | 2022 | 243 | 0.040 |
Why?
| | Data Collection | 1 | 2023 | 650 | 0.040 |
Why?
| | Dyspnea | 1 | 2022 | 251 | 0.040 |
Why?
| | In Situ Hybridization | 1 | 2020 | 317 | 0.040 |
Why?
| | North America | 1 | 2020 | 300 | 0.040 |
Why?
| | Australia | 1 | 2020 | 291 | 0.040 |
Why?
| | Kaplan-Meier Estimate | 1 | 2022 | 970 | 0.040 |
Why?
| | Appendiceal Neoplasms | 1 | 2019 | 28 | 0.040 |
Why?
| | United Kingdom | 1 | 2020 | 377 | 0.040 |
Why?
| | Germ-Line Mutation | 1 | 2020 | 180 | 0.040 |
Why?
| | Retrospective Studies | 3 | 2024 | 17438 | 0.040 |
Why?
| | Gene Expression Profiling | 2 | 2015 | 1792 | 0.030 |
Why?
| | Pregnancy Outcome | 1 | 2020 | 503 | 0.030 |
Why?
| | Antihypertensive Agents | 1 | 2021 | 519 | 0.030 |
Why?
| | Adenocarcinoma | 1 | 2024 | 927 | 0.030 |
Why?
| | Neoplasm Metastasis | 1 | 2019 | 693 | 0.030 |
Why?
| | Connecticut | 1 | 2016 | 25 | 0.030 |
Why?
| | Diabetes Mellitus | 1 | 2025 | 1101 | 0.030 |
Why?
| | Chromosomes, Human, Pair 6 | 1 | 2016 | 51 | 0.030 |
Why?
| | Physician-Patient Relations | 1 | 2020 | 597 | 0.030 |
Why?
| | Pilot Projects | 1 | 2021 | 1888 | 0.030 |
Why?
| | Risk Reduction Behavior | 1 | 2017 | 220 | 0.030 |
Why?
| | Women's Health | 1 | 2017 | 317 | 0.030 |
Why?
| | Europe | 1 | 2015 | 421 | 0.030 |
Why?
| | Neoplasm Invasiveness | 1 | 2016 | 504 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2019 | 1998 | 0.030 |
Why?
| | Global Health | 1 | 2017 | 403 | 0.030 |
Why?
| | Up-Regulation | 1 | 2016 | 841 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2016 | 1031 | 0.020 |
Why?
| | Gene Frequency | 1 | 2014 | 496 | 0.020 |
Why?
| | Male | 4 | 2025 | 73396 | 0.020 |
Why?
| | Biopsy | 1 | 2015 | 1075 | 0.020 |
Why?
| | Mammography | 1 | 2013 | 175 | 0.020 |
Why?
| | Genetic Association Studies | 1 | 2013 | 379 | 0.020 |
Why?
| | Prognosis | 1 | 2020 | 4351 | 0.020 |
Why?
| | DNA Methylation | 1 | 2016 | 725 | 0.020 |
Why?
| | Biomarkers | 1 | 2022 | 4340 | 0.020 |
Why?
| | Inflammation | 1 | 2022 | 2919 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2022 | 5899 | 0.020 |
Why?
| | Exercise | 1 | 2021 | 2213 | 0.020 |
Why?
| | Lung | 1 | 2022 | 4122 | 0.020 |
Why?
| | Research Design | 1 | 2015 | 1143 | 0.020 |
Why?
| | Genetic Variation | 1 | 2014 | 996 | 0.020 |
Why?
| | Cytokines | 1 | 2015 | 2081 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2013 | 3017 | 0.010 |
Why?
|
|
Cook's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|